AZ fills top R&D spot with Genentech's Bohen; Regulators OK Pfizer's Hospira deal;

> Genentech's Sean Bohen will take up the post as AstraZeneca's ($AZN) R&D chief. More

> Regulators have approved Pfizer's ($PFE) Hospira ($HSP) buyout deal, pending the divestiture of some sterile injectable drugs. Report

> Bayer HealthCare has launched a digital healthcare accelerator in Berlin. Report

> South Korean pharmaceutical companies are beefing up their presence in the global healthcare industry through global partnerships. More

> Merck KGaA will close down Bangalore GeNei, a company it acquired in 2009 to boost its capabilities in design, development and production of biological research products. More

And Finally... Google's ($GOOG) Life Sciences division is developing a wearable blood glucose monitor that could revolutionize diabetic care and treatment. Report

Suggested Articles

Roche’s Tecentriq didn't repeat its prior TNBC success when tested in tandem with chemo med paclitaxel in previously untreated metastatic patients.

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.

Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began rebuilding its oncology pipeline. Those efforts have finally paid off.